Functional Dyspepsia Market

Market Overview:

The 7 major functional dyspepsia markets reached a value of US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.99% during 2024-2034.

The functional dyspepsia market has been comprehensively analyzed in IMARC's new report titled "Functional Dyspepsia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Functional dyspepsia is a chronic digestive disorder characterized by recurrent and bothersome upper abdominal symptoms, despite no apparent structural abnormalities in the gastrointestinal tract. This condition affects the upper part of the digestive system, mainly the stomach, and can cause discomfort, pain, and a feeling of fullness during or after meals. The symptoms of the ailment commonly include persistent burning sensation or pain in the upper abdominal region, early satiety, bloating, belching, nausea, etc. These indications can significantly impact a patient's quality of life, leading to reduced appetite and potential weight loss. The diagnosis of functional dyspepsia typically involves a comprehensive medical history assessment, a physical examination, and possibly some tests to rule out various other conditions. These investigations may include blood workups, upper gastrointestinal endoscopy, and imaging studies. A crucial aspect of the diagnosis is the Rome criteria, which define the specific symptom patterns and duration required to classify the condition as functional dyspepsia.

The rising incidences of several associated risk factors, such as irritable bowel syndrome, excessive alcohol consumption, cigarette smoking, use of non-steroidal anti-inflammatory drugs, etc., are primarily driving the functional dyspepsia market. In addition to this, the inflating utilization of effective medications, like proton pump inhibitors, H2 receptor antagonists, prokinetic agents, etc., to alleviate or ease symptoms as well as improve patients' overall quality of life is also creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle modifications and dietary changes on account of their numerous advantages, including management of indigestion, prevention of disease progression, and enhancement of treatment outcomes, is further bolstering the market growth. Apart from this, the rising usage of non-pharmacological interventions that include stress reduction procedures and mindfulness practices to reduce stress, promote relaxation, and improve gastrointestinal health in individuals suffering from illness is also acting as another significant growth-inducing factor. Additionally, the emerging popularity of novel therapeutic approaches, such as neuromodulation techniques and gut-targeted therapies, which mainly target the nervous system and gut function, thereby addressing the root causes of the disease and potentially offering more effective solutions for patients, is expected to drive the functional dyspepsia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the functional dyspepsia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for functional dyspepsia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the functional dyspepsia market in any manner.

Key Highlights:

• Functional dyspepsia affects more than 20% of the population.
• It most frequently occurs in the age ranges 16-30 years and 31-45 years, i.e. among young people.
• A study revealed that the prevalence of functional dyspepsia is substantially higher in low- and middle-income nations, 37.9%, than in high-income countries, 10%, with a higher proportion among the Afro-Caribbean race, 47.9%.
• In research conducted in the United States, the United Kingdom, and Canada, an average prevalence rate of 10% was recorded, with a higher frequency in the United States, at 12%.
• A meta-analysis of epidemiological research found that female sex, smoking, use of non-steroidal anti-inflammatory medicines (NSAIDs), and H. pylori infection were risk factors for the condition, but with a moderate correlation between them.

Drugs:

Acotiamide (Z-338 or YM443) is a novel medication under development for treating functional dyspepsia. This candidate is a gastroprokinetic medication that increases acetylcholine release in the enteric nervous system by antagonizing muscarinic receptors and inhibiting acetycholinesterase.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the functional dyspepsia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the functional dyspepsia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current functional dyspepsia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the functional dyspepsia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the functional dyspepsia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the functional dyspepsia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of functional dyspepsia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of functional dyspepsia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of functional dyspepsia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with functional dyspepsia across the seven major markets?
• What is the size of the functional dyspepsia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of functional dyspepsia?
• What will be the growth rate of patients across the seven major markets?
   

Functional Dyspepsia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for functional dyspepsia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the functional dyspepsia market?
• What are the key regulatory events related to the functional dyspepsia market?
• What is the structure of clinical trial landscape by status related to the functional dyspepsia market?
• What is the structure of clinical trial landscape by phase related to the functional dyspepsia market?
• What is the structure of clinical trial landscape by route of administration related to the functional dyspepsia market?